Discovery and biological activity of computer-assisted drug designed Akt pathway inhibitors
Nne E Uko1, Osman F Güner1, Lillie M A Barnett1
1Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.
Abstract:
The P13K/Akt pathway is a growth-regulating cellular signaling pathway that is over-activated in numerous human cancers. A novel series of Akt pathway inhibitors were identified using iterative pharmacophore modeling, energy-based calculations, and property predictions of known Akt inhibitors. Inhibitory effects on activation of Akt and growth of human neoplastic cells are reported. Results show variable inhibitory effects of three selected compounds on Akt phosphorylation at a key activation site, and on proliferation of tumorigenic cells. We identify one lead compound with potent inhibitory activity on both human carcinoma cell proliferation and Akt activation.
Insights
Researchers identified novel inhibitors targeting the over-activated PI3K/Akt pathway in cancer. One lead compound effectively inhibited human carcinoma cell proliferation and Akt activation, offering a promising therapeutic strategy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The phosphoinositide 3-kinase (PI3K)/Akt pathway is a critical regulator of cell growth and survival.
- Aberrant activation of the PI3K/Akt pathway is implicated in the pathogenesis of various human cancers.
- Targeting this pathway presents a promising strategy for cancer therapy.
Purpose of the Study:
- To identify and characterize novel inhibitors of the PI3K/Akt pathway.
- To evaluate the efficacy of these inhibitors in blocking Akt activation and neoplastic cell proliferation.
Main Methods:
- Iterative pharmacophore modeling was employed to design potential Akt pathway inhibitors.
- Energy-based calculations and property predictions guided the selection of candidate compounds.
- In vitro assays were performed to assess the inhibitory effects on Akt phosphorylation and cancer cell proliferation.
Main Results:
- Three novel compounds demonstrated variable inhibitory effects on Akt phosphorylation.
- These compounds also exhibited differential impacts on the proliferation of human neoplastic cells.
- One lead compound exhibited potent inhibition of both human carcinoma cell proliferation and Akt activation.
Conclusions:
- The identified lead compound shows significant potential as an Akt pathway inhibitor for cancer treatment.
- Targeted inhibition of the PI3K/Akt pathway is a viable therapeutic approach for human cancers.
- Further investigation of this lead compound is warranted for its clinical development.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Discovery: Overview
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Antihypertensive Drugs: Direct Renin Inhibitors
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...


